Currently, BRAF inhibitor vemurafenib and MEK inhibitor trametinib are the most common drugs used for the treatment of melanoma (Guo et al., 2021; Chiavarini et al., 2022; Porcelli et al., 2022). This evidence concerns the gene BRAF and melanoma.